Machine learning-assisted discovery of GPCR bioactive ligands
暂无分享,去创建一个
[1] Andreas Bender,et al. Discovering Highly Potent Molecules from an Initial Set of Inactives Using Iterative Screening , 2018, J. Chem. Inf. Model..
[2] Robert P. Sheridan,et al. Deep Neural Nets as a Method for Quantitative Structure-Activity Relationships , 2015, J. Chem. Inf. Model..
[3] Alireza Mehridehnavi,et al. Neural network and deep-learning algorithms used in QSAR studies: merits and drawbacks. , 2018, Drug discovery today.
[4] Károly Héberger,et al. Why is Tanimoto index an appropriate choice for fingerprint-based similarity calculations? , 2015, Journal of Cheminformatics.
[5] Gaël Varoquaux,et al. Scikit-learn: Machine Learning in Python , 2011, J. Mach. Learn. Res..
[6] David D. Lewis,et al. Naive (Bayes) at Forty: The Independence Assumption in Information Retrieval , 1998, ECML.
[7] Sean Ekins,et al. Comparison of Deep Learning With Multiple Machine Learning Methods and Metrics Using Diverse Drug Discovery Data Sets. , 2017, Molecular pharmaceutics.
[8] T. Klabunde,et al. Identification of nonpeptidic urotensin II receptor antagonists by virtual screening based on a pharmacophore model derived from structure-activity relationships and nuclear magnetic resonance studies on urotensin II. , 2002, Journal of medicinal chemistry.
[9] David W. Hosmer,et al. Applied Logistic Regression , 1991 .
[10] Gustavo Henrique Goulart Trossini,et al. Use of machine learning approaches for novel drug discovery , 2016, Expert opinion on drug discovery.
[11] Ruben Abagyan,et al. Identifying ligands at orphan GPCRs: current status using structure‐based approaches , 2016, British journal of pharmacology.
[12] Leo Breiman,et al. Random Forests , 2001, Machine Learning.
[13] Antony J. Williams,et al. Bigger data, collaborative tools and the future of predictive drug discovery , 2014, Journal of Computer-Aided Molecular Design.
[14] Nikil Wale,et al. Machine learning in drug discovery and development , 2011 .
[15] A. Bender,et al. Analysis of Pharmacology Data and the Prediction of Adverse Drug Reactions and Off‐Target Effects from Chemical Structure , 2007, ChemMedChem.
[16] David E. Gloriam,et al. Comprehensive repertoire and phylogenetic analysis of the G protein-coupled receptors in human and mouse. , 2006, Genomics.
[17] Andreas Bender,et al. How Similar Are Similarity Searching Methods? A Principal Component Analysis of Molecular Descriptor Space , 2009, J. Chem. Inf. Model..
[18] Alexios Koutsoukas,et al. Deep-learning: investigating deep neural networks hyper-parameters and comparison of performance to shallow methods for modeling bioactivity data , 2017, Journal of Cheminformatics.
[19] P Ryan,et al. Novel Data‐Mining Methodologies for Adverse Drug Event Discovery and Analysis , 2012, Clinical pharmacology and therapeutics.
[20] Joanna L. Sharman,et al. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands , 2015, Nucleic Acids Res..
[21] George Papadatos,et al. myChEMBL: a virtual machine implementation of open data and cheminformatics tools , 2014, Bioinform..
[22] R. Glen,et al. Molecular similarity: a key technique in molecular informatics. , 2004, Organic & biomolecular chemistry.
[23] David E. Gloriam,et al. Trends in GPCR drug discovery: new agents, targets and indications , 2017, Nature Reviews Drug Discovery.
[24] Nello Cristianini,et al. An Introduction to Support Vector Machines and Other Kernel-based Learning Methods , 2000 .
[25] Alán Aspuru-Guzik,et al. Convolutional Networks on Graphs for Learning Molecular Fingerprints , 2015, NIPS.
[26] Adam J Pawson,et al. International Union of Basic and Clinical Pharmacology. LXXXVIII. G Protein-Coupled Receptor List: Recommendations for New Pairings with Cognate Ligands , 2013, Pharmacological Reviews.
[27] Xian Jin,et al. Stereoselective virtual screening of the ZINC database using atom pair 3D-fingerprints , 2015, Journal of Cheminformatics.
[28] Bryan L Roth,et al. Discovery of new GPCR ligands to illuminate new biology. , 2017, Nature chemical biology.
[29] Luca Antiga,et al. Automatic differentiation in PyTorch , 2017 .
[30] Gerhard Hessler,et al. Drug Design Strategies for Targeting G‐Protein‐Coupled Receptors , 2002, Chembiochem : a European journal of chemical biology.
[31] Claudio Ciferri,et al. Cryo-EM in drug discovery: achievements, limitations and prospects , 2018, Nature Reviews Drug Discovery.
[32] C. Lipinski. Drug-like properties and the causes of poor solubility and poor permeability. , 2000, Journal of pharmacological and toxicological methods.
[33] Wei Liu,et al. Femtosecond crystallography of membrane proteins in the lipidic cubic phase , 2014, Philosophical Transactions of the Royal Society B: Biological Sciences.
[34] William Thomsen,et al. Functional assays for screening GPCR targets. , 2005, Current opinion in biotechnology.
[35] Bhaskar Datta,et al. Molecular docking, molecular modeling, and molecular dynamics studies of azaisoflavone as dual COX-2 inhibitors and TP receptor antagonists , 2018, Journal of Molecular Modeling.
[36] Sebastian Raschka,et al. Protein–ligand interfaces are polarized: discovery of a strong trend for intermolecular hydrogen bonds to favor donors on the protein side with implications for predicting and designing ligand complexes , 2018, Journal of Computer-Aided Molecular Design.
[37] D. Sengupta,et al. Characterizing clinically relevant natural variants of GPCRs using computational approaches. , 2017, Methods in cell biology.
[38] Thomas Blaschke,et al. The rise of deep learning in drug discovery. , 2018, Drug discovery today.
[39] Francoise Neil D. Dacanay,et al. Molecular Affinity of Mabolo Extracts to an Octopamine Receptor of a Fruit Fly , 2017, Molecules.
[40] Arthur Christopoulos,et al. Dominant Negative G Proteins Enhance Formation and Purification of Agonist-GPCR-G Protein Complexes for Structure Determination. , 2018, ACS pharmacology & translational science.
[41] S. Garland. Are GPCRs Still a Source of New Targets? , 2013, Journal of biomolecular screening.
[42] J. Simms,et al. Lifting the lid on GPCRs: the role of extracellular loops , 2011, British journal of pharmacology.
[43] Ting Wang,et al. Application of Breiman's Random Forest to Modeling Structure-Activity Relationships of Pharmaceutical Molecules , 2004, Multiple Classifier Systems.
[44] Fei Luo,et al. Pairwise input neural network for target-ligand interaction prediction , 2014, 2014 IEEE International Conference on Bioinformatics and Biomedicine (BIBM).
[45] Sebastian Raschka,et al. Detecting the native ligand orientation by interfacial rigidity: SiteInterlock , 2016, Proteins.
[46] Meir Glick,et al. Prediction of Biological Targets for Compounds Using Multiple-Category Bayesian Models Trained on Chemogenomics Databases , 2006, J. Chem. Inf. Model..
[47] Sebastian Raschka,et al. Automated Inference of Chemical Discriminants of Biological Activity. , 2018, Methods in molecular biology.
[48] P. Hawkins,et al. Comparison of shape-matching and docking as virtual screening tools. , 2007, Journal of medicinal chemistry.
[49] Anthony Gitter,et al. Practical Model Selection for Prospective Virtual Screening , 2018, bioRxiv.
[50] John J. Irwin,et al. ZINC 15 – Ligand Discovery for Everyone , 2015, J. Chem. Inf. Model..
[51] J. Baell,et al. Chemistry: Chemical con artists foil drug discovery , 2014, Nature.
[52] Robert P. Sheridan,et al. Random Forest: A Classification and Regression Tool for Compound Classification and QSAR Modeling , 2003, J. Chem. Inf. Comput. Sci..
[53] A. Zhavoronkov. Artificial Intelligence for Drug Discovery, Biomarker Development, and Generation of Novel Chemistry. , 2018, Molecular pharmaceutics.
[54] Sean Ekins. The Next Era: Deep Learning in Pharmaceutical Research , 2016, Pharmaceutical Research.
[55] Jan Jakubík,et al. Towards predictive docking at aminergic G-protein coupled receptors , 2015, Journal of Molecular Modeling.
[56] Anne E Carpenter,et al. Opportunities and obstacles for deep learning in biology and medicine , 2017, bioRxiv.
[57] Andreas Evers,et al. Virtual screening of biogenic amine-binding G-protein coupled receptors: comparative evaluation of protein- and ligand-based virtual screening protocols. , 2005, Journal of medicinal chemistry.
[58] H. van de Waterbeemd,et al. ADMET in silico modelling: towards prediction paradise? , 2003, Nature reviews. Drug discovery.
[59] David Ryan Koes,et al. Pharmit: interactive exploration of chemical space , 2016, Nucleic Acids Res..
[60] Hyunju Lee,et al. Predicting Drug-Target Interactions Using Drug-Drug Interactions , 2013, PloS one.
[61] Ksenia Korshunova,et al. Predicting ligand binding poses for low-resolution membrane protein models: Perspectives from multiscale simulations. , 2018, Biochemical and biophysical research communications.
[62] Hao Zhu,et al. Comparing Multiple Machine Learning Algorithms and Metrics for Estrogen Receptor Binding Prediction. , 2018, Molecular pharmaceutics.
[63] Sun Choi,et al. Exploring G Protein-Coupled Receptors (GPCRs) Ligand Space via Cheminformatics Approaches: Impact on Rational Drug Design , 2018, Front. Pharmacol..
[64] Antonio Lavecchia,et al. Machine-learning approaches in drug discovery: methods and applications. , 2015, Drug discovery today.
[65] Patrick Hop,et al. Geometric Deep Learning Autonomously Learns Chemical Features That Outperform Those Engineered by Domain Experts. , 2018, Molecular pharmaceutics.
[66] Huikun Zhang,et al. Machine Learning Consensus Scoring Improves Performance Across Targets in Structure-Based Virtual Screening , 2017, J. Chem. Inf. Model..
[67] Bartek Wilczynski,et al. Biopython: freely available Python tools for computational molecular biology and bioinformatics , 2009, Bioinform..
[68] Amir Barati Farimani,et al. Machine Learning Harnesses Molecular Dynamics to Discover New $\mu$ Opioid Chemotypes , 2018 .
[69] Sebastian Raschka,et al. Python Machine Learning , 2015 .
[70] George Papadatos,et al. The ChEMBL bioactivity database: an update , 2013, Nucleic Acids Res..
[71] Dan Li,et al. ADMET Evaluation in Drug Discovery. 16. Predicting hERG Blockers by Combining Multiple Pharmacophores and Machine Learning Approaches. , 2016, Molecular pharmaceutics.
[72] D. Jacobs,et al. Protein flexibility predictions using graph theory , 2001, Proteins.
[73] Gerhard Hessler,et al. Drug Design Strategies for Targeting G-Protein-Coupled Receptors , 2002 .
[74] George Papadatos,et al. Beyond the hype: deep neural networks outperform established methods using a ChEMBL bioactivity benchmark set , 2017, bioRxiv.
[75] Sebastian Raschka,et al. MLxtend: Providing machine learning and data science utilities and extensions to Python's scientific computing stack , 2018, J. Open Source Softw..
[76] Adam J. Pawson,et al. IUPHAR/BPS guide to pharmacology , 2020 .
[77] Michael J. Keiser,et al. Adversarial Controls for Scientific Machine Learning. , 2018, ACS chemical biology.
[78] Carlos Guestrin,et al. "Why Should I Trust You?": Explaining the Predictions of Any Classifier , 2016, ArXiv.
[79] Tingjun Hou,et al. ADME evaluation in drug discovery , 2002, Journal of molecular modeling.
[80] Nan Liu,et al. Enabling the hypothesis-driven prioritization of ligand candidates in big databases: Screenlamp and its application to GPCR inhibitor discovery for invasive species control , 2018, bioRxiv.
[81] Woody Sherman,et al. Analysis and comparison of 2D fingerprints: insights into database screening performance using eight fingerprint methods , 2010, J. Cheminformatics.
[82] Daniel Reker,et al. Small Random Forest Models for Effective Chemogenomic Active Learning , 2017 .
[83] Sebastian Raschka,et al. BioPandas: Working with molecular structures in pandas DataFrames , 2017, J. Open Source Softw..
[84] Bernd Beck,et al. A support vector machine approach to classify human cytochrome P450 3A4 inhibitors , 2005, J. Comput. Aided Mol. Des..
[85] Alex M. Clark,et al. Open Source Bayesian Models. 2. Mining a "Big Dataset" To Create and Validate Models with ChEMBL , 2015, J. Chem. Inf. Model..
[86] Hugo Ceulemans,et al. Large-scale comparison of machine learning methods for drug target prediction on ChEMBL† †Electronic supplementary information (ESI) available: Overview, Data Collection and Clustering, Methods, Results, Appendix. See DOI: 10.1039/c8sc00148k , 2018, Chemical science.
[87] Antonella Ciancetta,et al. New Trends in Inspecting GPCR‐ligand Recognition Process: the Contribution of the Molecular Modeling Section (MMS) at the University of Padova , 2016, Molecular informatics.
[88] David Madigan,et al. Large‐scale regression‐based pattern discovery: The example of screening the WHO global drug safety database , 2010, Stat. Anal. Data Min..
[89] P. Willett,et al. Similarity-based virtual screening using 2D fingerprints. , 2006, Drug discovery today.
[90] Yuan Yu,et al. TensorFlow: A system for large-scale machine learning , 2016, OSDI.
[91] Peter Willett,et al. Similarity-based virtual screening using 2D fingerprints. , 2006, Drug discovery today.